home.social

#drugrepurposing — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #drugrepurposing, aggregated by home.social.

  1. DATE: July 17, 2026 at 12:19AM
    SOURCE: SCIENCE DAILY MIND-BRAIN FEED

    TITLE: New Alzheimer's drug repairs DNA damage and reduces brain inflammation

    URL: sciencedaily.com/releases/2026

    A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.

    URL: sciencedaily.com/releases/2026

    -------------------------------------------------

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #AlzheimersDrug #DNARepair #Neuroinflammation #KCL286 #AlzheimersResearch #DNA_damage #BrainHealth #NeurodegenerativeDisease #ClinicalTrials #DrugRepurposing

  2. DATE: July 17, 2026 at 12:19AM
    SOURCE: SCIENCE DAILY MIND-BRAIN FEED

    TITLE: New Alzheimer's drug repairs DNA damage and reduces brain inflammation

    URL: sciencedaily.com/releases/2026

    A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.

    URL: sciencedaily.com/releases/2026

    -------------------------------------------------

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #AlzheimersDrug #DNARepair #Neuroinflammation #KCL286 #AlzheimersResearch #DNA_damage #BrainHealth #NeurodegenerativeDisease #ClinicalTrials #DrugRepurposing

  3. DATE: July 17, 2026 at 12:19AM
    SOURCE: SCIENCE DAILY MIND-BRAIN FEED

    TITLE: New Alzheimer's drug repairs DNA damage and reduces brain inflammation

    URL: sciencedaily.com/releases/2026

    A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.

    URL: sciencedaily.com/releases/2026

    -------------------------------------------------

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #AlzheimersDrug #DNARepair #Neuroinflammation #KCL286 #AlzheimersResearch #DNA_damage #BrainHealth #NeurodegenerativeDisease #ClinicalTrials #DrugRepurposing

  4. DATE: June 16, 2026 at 02:48AM
    SOURCE: SCIENCE DAILY MIND-BRAIN FEED

    TITLE: Copper drug clears toxic Alzheimer’s proteins and restores memory

    URL: sciencedaily.com/releases/2026

    A copper-based compound restored the brain’s ability to clear toxic Alzheimer’s proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments. The findings point to a potentially fast-tracked new treatment strategy because the drug has already been tested in humans for other neurological conditions.

    URL: sciencedaily.com/releases/2026

    -------------------------------------------------

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #CopperDrug #AlzheimersResearch #MemoryRestoration #AmyloidClearing #NeurodegenerativeTherapy #CopperBasedTherapy #BrainHealth #DrugRepurposing #NeurologyNews #CognitiveImprovement

  5. DATE: June 16, 2026 at 02:48AM
    SOURCE: SCIENCE DAILY MIND-BRAIN FEED

    TITLE: Copper drug clears toxic Alzheimer’s proteins and restores memory

    URL: sciencedaily.com/releases/2026

    A copper-based compound restored the brain’s ability to clear toxic Alzheimer’s proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments. The findings point to a potentially fast-tracked new treatment strategy because the drug has already been tested in humans for other neurological conditions.

    URL: sciencedaily.com/releases/2026

    -------------------------------------------------

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #CopperDrug #AlzheimersResearch #MemoryRestoration #AmyloidClearing #NeurodegenerativeTherapy #CopperBasedTherapy #BrainHealth #DrugRepurposing #NeurologyNews #CognitiveImprovement

  6. DATE: June 16, 2026 at 02:48AM
    SOURCE: SCIENCE DAILY MIND-BRAIN FEED

    TITLE: Copper drug clears toxic Alzheimer’s proteins and restores memory

    URL: sciencedaily.com/releases/2026

    A copper-based compound restored the brain’s ability to clear toxic Alzheimer’s proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments. The findings point to a potentially fast-tracked new treatment strategy because the drug has already been tested in humans for other neurological conditions.

    URL: sciencedaily.com/releases/2026

    -------------------------------------------------

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #CopperDrug #AlzheimersResearch #MemoryRestoration #AmyloidClearing #NeurodegenerativeTherapy #CopperBasedTherapy #BrainHealth #DrugRepurposing #NeurologyNews #CognitiveImprovement

  7. It's interesting that they paired a talk on ergothioneine, which is primarily thought of as an anti-oxidant (though as discussed in the video, there may be more to its MOA) with hemin, which is a potent pro-oxidant.

    There was an in vitro study that suggested hemin might be useful in acute Covid, but it never went anywhere AFAIK. The paper is still interesting for background on hemin as an HO-1 inducer -
    pmc.ncbi.nlm.nih.gov/articles/

    #hemin #HemeOxygenase #DrugRepurposing

  8. Erythromycin has therapeutic efficacy on muscle fatigue acting specifically on orosomucoid to increase muscle bioenergetics and physiological parameters of endurance [2020]

    abstract:
    pubmed.ncbi.nlm.nih.gov/327772

    preprint can be downloaded here:
    papers.ssrn.com/sol3/papers.cf

    #orosomucoid #fatigue #erythromycin #DrugRepurposing #DrugDevelopment

  9. Erythromycin has therapeutic efficacy on muscle fatigue acting specifically on orosomucoid to increase muscle bioenergetics and physiological parameters of endurance [2020]

    abstract:
    pubmed.ncbi.nlm.nih.gov/327772

    preprint can be downloaded here:
    papers.ssrn.com/sol3/papers.cf

    #orosomucoid #fatigue #erythromycin #DrugRepurposing #DrugDevelopment

  10. Erythromycin has therapeutic efficacy on muscle fatigue acting specifically on orosomucoid to increase muscle bioenergetics and physiological parameters of endurance [2020]

    abstract:
    pubmed.ncbi.nlm.nih.gov/327772

    preprint can be downloaded here:
    papers.ssrn.com/sol3/papers.cf

    #orosomucoid #fatigue #erythromycin #DrugRepurposing #DrugDevelopment

  11. Erythromycin has therapeutic efficacy on muscle fatigue acting specifically on orosomucoid to increase muscle bioenergetics and physiological parameters of endurance [2020]

    abstract:
    pubmed.ncbi.nlm.nih.gov/327772

    preprint can be downloaded here:
    papers.ssrn.com/sol3/papers.cf

    #orosomucoid #fatigue #erythromycin #DrugRepurposing #DrugDevelopment

  12. Brayden Yellman, MD | Underappreciated Co-Morbidities in ME/CFS
    video uploaded Oct. 16, 2025
    youtu.be/od0epKW19og

    [13:03] hydroxyurea used to treat a person with POTS and MCAS

    Here's an article on the topic:

    Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: retrospective case series [2022]
    pmc.ncbi.nlm.nih.gov/articles/

    "First used 60 years ago for chronic myeloproliferative neoplasms, HU is now standard of care in reducing the severity of sickle cell disease (SCD) (McGann and Ware 2015). In this context, it is of interest that in animal models and human subjects with SCD, medications that reduce MC activation decreased bone pain (Vincent et al. 2013, 2016). HU also inhibits replication of human immunodeficiency virus-1 (HIV-1) and has been used in therapy of cyanotic congenital heart disease (Lori and Lisziewicz 2000; Reiss et al. 2007). A theoretic explanation for effectiveness of HU in these diseases include reducing MC activity independent of anti-proliferative effects. HU could decrease activity and ability of GI mucosal MCs that capture HIV-1 and mediate trans-infection of CD4 + T cells (Jiang et al. 2015). Similarly, HU could reduce the activity of the increased numbers of chymase-containing MCs in lung tissue of congenital heart disease patients and, thereby, decrease severity of these pulmonary and cardiac diseases (Hamada et al. 1999)."

    The mechanisms are probably quite complex. One facet is that hydroxyurea increases fetal hemoglobin production and RBC membrane flexibility - which could increase O2 perfusion. Hypoxia activates mast cells.

    #MECFS #MCAS #POTS #DrugRepurposing #hydroxyurea #MastCells #immunology

  13. 📖 💊 New Issue Alert!

    Drug Repurposing Vol 2, Issue 1 is out! 5 exciting articles explore AI, chemoinformatics, VR collaboration, and more — showing how existing drugs can find new therapeutic uses.

    #DrugRepurposing #OpenScience #DrugDiscovery

  14. A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID
    pubs.acs.org/doi/full/10.1021/

    lots of details on #pathophysiology in this review

    #MECFS #LongCovid #metformin #DrugRepurposing #medicine #health
    #WASF3

  15. A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID
    pubs.acs.org/doi/full/10.1021/

    lots of details on #pathophysiology in this review

    #MECFS #LongCovid #metformin #DrugRepurposing #medicine #health
    #WASF3

  16. A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID
    pubs.acs.org/doi/full/10.1021/

    lots of details on #pathophysiology in this review

    #MECFS #LongCovid #metformin #DrugRepurposing #medicine #health
    #WASF3

  17. A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID
    pubs.acs.org/doi/full/10.1021/

    lots of details on #pathophysiology in this review

    #MECFS #LongCovid #metformin #DrugRepurposing #medicine #health
    #WASF3

  18. 'DrugRxiv' is an open community resource for preprints from the field of #DrugRepurposing. Preprints have increasingly become an essential part of #OpenScience approaches because they combine early and open sharing of #Research results with #OpenAccess and open peer review: drugrepocentral.scienceopen.co

  19. 🌍💊 Gemeinsam für Innovation in der Medizin: Das REPO4EU-Projektkonsortium traf sich am 15. und 16. Jänner 2025 zur General Assembly in Brüssel!

    Im Fokus: Die Weiterentwicklung einer Plattform für „drug repurposing“, um bestehende Medikamente für neue therapeutische Ziele nutzbar zu machen.

    Wir waren vor Ort und begleiten die Plattformentwicklung in rechtlicher Hinsicht.

    Danke an alle Projektpartner*innen.

    researchinstitute.at/repo4eu-g

    #DrugRepurposing #AIAct #Innovation #Forschung #REPO4EU

  20. recent review -
    Nguyen, J., Nguyen, T. Q., Han, B., & Hoang, B. X. (2024).
    Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research, 44(9), 3725–3735. doi.org/10.21873/anticanres.17

    #cancer #DrugRepurposing

  21. new paper: "Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?" doi.org/10.3389/fmed.2024.1425

    "Rett syndrome (RTT) and Rett-like syndromes [i.e., CDKL5 deficiency disorder (CDD) and FOXG1-syndrome] represent rare yet profoundly impactful neurodevelopmental disorders (NDDs). [..] The current landscape of DR efforts in these syndromes is thoroughly examined [..]"

    #rettSyndrome #bioinformatics #drugRepurposing

  22. new paper: "Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?" doi.org/10.3389/fmed.2024.1425

    "Rett syndrome (RTT) and Rett-like syndromes [i.e., CDKL5 deficiency disorder (CDD) and FOXG1-syndrome] represent rare yet profoundly impactful neurodevelopmental disorders (NDDs). [..] The current landscape of DR efforts in these syndromes is thoroughly examined [..]"

    #rettSyndrome #bioinformatics #drugRepurposing

  23. "A foundation model for clinician-centered drug repurposing"
    There is a strong need for #drugrepurposing given how much clinical trials cost and how many drugs are already developed.
    TxGNN predicts indications & contraindications:
    nature.com/articles/s41591-024
    #medTwitter #medicine #AI

  24. "A foundation model for clinician-centered drug repurposing"
    There is a strong need for #drugrepurposing given how much clinical trials cost and how many drugs are already developed.
    TxGNN predicts indications & contraindications:
    nature.com/articles/s41591-024
    #medTwitter #medicine #AI